KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Treasury Shares (2017 - 2025)

NovoCure's Treasury Shares history spans 9 years, with the latest figure at $13.1 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 8.85% year-over-year to $13.1 million; the TTM value through Dec 2025 reached $13.1 million, up 8.85%, while the annual FY2025 figure was $13.1 million, 8.85% up from the prior year.
  • Treasury Shares for Q4 2025 was $13.1 million at NovoCure, down from $13.6 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $13.9 million in Q1 2025 and bottomed at $4.5 million in Q3 2021.
  • The 5-year median for Treasury Shares is $5.8 million (2023), against an average of $8.4 million.
  • The largest annual shift saw Treasury Shares dropped 2.8% in 2021 before it soared 142.87% in 2024.
  • A 5-year view of Treasury Shares shows it stood at $4.5 million in 2021, then grew by 20.59% to $5.4 million in 2022, then grew by 8.1% to $5.8 million in 2023, then surged by 107.58% to $12.1 million in 2024, then rose by 8.85% to $13.1 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Treasury Shares are $13.1 million (Q4 2025), $13.6 million (Q3 2025), and $13.7 million (Q2 2025).